Our Mission
ImmuNovX Biotech is an early-stage company that is pioneering the rapid, scalable production of customized, high-purity antigens against pathogens that contain DNA to enable highly-effective, safe vaccines.
Our Science
Our Antig3NX™ platform technology chemically binds the DNA of treated pathogens via a cell-free manufacturing process, resulting in live-attenuated, replication-defective antigens against DNA-containing pathogens:
Faster, straightforward, better.
Enabling a novel class of DNA vaccines.
Partnering
ImmuNovX is actively seeking partners and collaborators, and would value the opportunity to discuss potential synergies.